United Therapeutics Corporation (UTHR) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
United Therapeutics Corporation (UTHR) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (88% profit margin, 20% return on capital) with steady institutional support. Even if the broader market gets choppy, the company’s underlying cash engine and big-money support put the odds in buyers’ favor.
How UTHR Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | 87.9% | 46.9% | $1.33B | $1.04B | 20% |
| FY 2024 | $2.88B | 89.2% | 47.9% | $1.20B | $1.08B | 21.1% |
| FY 2023 | $2.33B | 44% | 50.9% | $984.8M | $873.3M | 11.1% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring UTHR)
- ✓Live walkthrough of UTHR's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
UTHR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +10.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on UTHR today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for UTHR. Explore sector supply chains on /butterfly.
UTHR Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is United Therapeutics Corporation (UTHR)?
In FY 2025 (10-K), UTHR converted $3.2B of revenue into a 87.9% gross margin, 46.9% operating margin, and $1.0B in free cash flow (32.7% FCF margin).